Research programme: doxorubicin nanoparticles - Capsulution Pharma AG
Alternative Names: Doxorubicin nanoparticles - NanoDelLatest Information Update: 14 Jan 2022
At a glance
- Originator NanoDel Technologies
- Developer Capsulution Pharma
- Class Anthracyclines; Antineoplastics; Cytostatic antibiotics; Doxorubicins; Small molecules
- Mechanism of Action DNA intercalators; Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Brain cancer
Most Recent Events
- 18 May 2011 No development reported - Preclinical for Brain cancer in Germany (unspecified route)
- 17 Aug 2005 Preclinical trials in Brain cancer in Germany (unspecified route)